Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
73,035.17
(
-0.06%
)
News Focus
News Focus
Post# of 257388
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122862
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Praveen post# 20771

Monday, 12/19/2005 12:22:05 AM

Monday, December 19, 2005 12:22:05 AM

Post# of 257388
>most of TEVA's revenues are from copaxone if I am right...<

No—not even close. TEVA has total annualized sales of more than $5B (1.32B in the latest quarter), and Copaxone represents 10-15% of the total, after adjusting for TEVA’s 50% stake. (SNY owns the other 50% of Copaxone.)

>…and also MNTA is planning to file a biogeneric for Copaxone…<

That’s news to me. Can you provide a source? T.i.a. Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today